

Adherium achieves major commercial milestone in Allergy Partners rollout

Highlights:

- Adherium's collaboration with Allergy Partners has reached a key commercial inflection point, translating technology deployment into recurring revenue through the Company's Remote Patient Monitoring (RPM) fee-for-service business model.
- The Company has achieved rapid expansion in over 110 Allergy Partners clinic locations across the U.S. with almost 70% of the network now activated and driving patient onboarding.
- Progress supports Adherium's CY25 goal of approximately 4,000 active patients across its U.S. Remote Patient Monitoring (RPM) Program and partner ecosystem, signalling strong commercial momentum.

Melbourne, Australia – 26 November 2025: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® (Hailie) platform, today announced significant progress in its collaboration with Allergy Partners, one of the largest and most respected allergy and asthma networks in the United States.

This milestone represents a key commercial inflection point for Adherium — translating technology deployment into patient-driven, recurring revenue through the Company's Remote Patient Monitoring (RPM) fee-for-service business model.

Rapid expansion across the Allergy Partners network

Since Adherium assumed responsibility for patient onboarding Adherium and Allergy Partners have accelerated the rollout of Hailie sensors and digital monitoring services across 110 clinic locations nationwide, in less than six months. The Allergy Partners system serves an estimated 90,000 asthma patients eligible for participation in Adherium's RPM Hailie® Smartinhaler platform.

What began as a network agreement has now progressed into a fully managed, execution-driven collaboration, with Adherium overseeing the end-to-end activation of Allergy Partner patients onto its fee-for-service RPM workflow.

With almost 70% of the network now participating in Adherium's digital workflow, these clinics have become an engine for Adherium's Remote Patient Monitoring (RPM) program. Each active clinic represents a recurring revenue opportunity as new patients are onboarded and monitored under reimbursable RPM/RTM codes.

This structure establishes a scalable and predictable revenue stream, directly linking clinical activation to recurring cash flow, while strengthening long-term engagement between clinicians, patients, and Adherium's technology platform.

As of 26 November 2025:

- Adherium has activated clinics across 70% of the Allergy Partner network
- Nearly 700 Allergy Partners patients have been enrolled and actively monitored within the last six months
- Five additional Allergy Partner clinics are expected to complete activation by year-end

Allergy Partners CEO, William A. McCann MD, commented: *"This clinical collaboration has not only supported our patients but also given our clinicians the insights needed to deliver better, more proactive care. Utilising Hailie, we're seeing these results firsthand, and they are truly game-changing for chronic respiratory management. For years, adherence to asthma controller therapy has been one of our biggest challenges. Now, digital tools like Hailie are proving they can genuinely change the trajectory of asthma and COPD care."*

Adherium CEO, Dawn Bitz, said: *"Our partnership with Allergy Partners demonstrates that Adherium has transitioned from proof-of-concept to proof-of-performance. More than three quarters of one of America's largest allergy and asthma networks is now live on our platform, with patient adoption growing every month. This level of operational traction is exactly what investors have been waiting to see and it's only the beginning."*

Driving the standard of digital respiratory care

Through the partnership, Allergy Partners providers can seamlessly integrate Adherium's FDA-cleared Hailie sensors and remote monitoring services into clinical workflows, enabling real-time adherence tracking, proactive outreach, and early identification of patients at risk of breathing attacks. Allergy Partners is also launching a new patient-facing Hailie resource page on its website featuring patient resources, testimonials, and a direct link for patients to learn more about the Hailie platform.

Operational and strategic significance

This progress with Allergy Partners underscores Adherium's commercial execution discipline and ability to scale complex rollouts across large, decentralised specialty networks. The growing patient base and high clinic adoption rate support Adherium's year-end goal of reaching approximately 4,000 active patients across its US RPM and partner ecosystem, solidifying momentum heading into 2026.

- ENDS -



ASX Release

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com

About Allergy Partners

Allergy Partners is the nation's largest single-specialty allergy, asthma, and immunology practice, serving communities through more than 110 clinics across 20 states. For over 45 years, Allergy Partners has remained dedicated to improving the quality of life for patients through compassionate, personalized care and the advancement of allergy and asthma treatment. Led by board-certified allergist-immunologists and supported by a collaborative national network, Allergy Partners combines clinical expertise with ongoing research and innovation to deliver better outcomes for patients and families. The company is headquartered in Asheville, North Carolina. For more information visit www.allergypartners.com.

For personal use only